Literature DB >> 235559

Response of the kallikrein-kinin and renin-angiotensin systems to saline infusion and upright posture.

P Y Wong, R C Talamo, G H Williams, R W Colman.   

Abstract

The possibility that bradykinin, a potent vasodilator, might be a physiological antagonist of the renin-angiotensin system was investigated. 11 norman subjects, ranging in age from 21 to 33 yr were studied. Seven of the subjects were given a 10 meq sodium, 100 meq potassium, 2500 ml isocaloric diet. After metabolic balance was achieved, they were infused with either 1 liter of 5 per cent glucose over 2 h or 2 liters of 0.9 per cent saline over 4 h. During the infusions, plasma renin activity (PRA), angiotensin II (A II), prekallikrein, bradykinin, and aldosterone levels were frequently determined. Plasma prekallikrein and kallikrein inhibitor did not change during the infusion of either glucose or saline. In subjects receiving saline, plasma bradykinin fell from 3.9 plus or minus 1.5 (SEM) ng/ml at 0 min to 0.93 plus or minus 0.2 at 30 min and 0.95 plus or minus 0.3 at 120 min. These changes paralleled the decrease in PRA over the same period (7.9 plus or minus 1.3 ng/ml/h to 5.6 plus or minus 0.8 at 30 min and 3.5 plus or minus 0.7 at 120 min). Similarly, A II fell from 113 plus or minus 12 pg/ml to 62 plus or minus 10 and 48 plus or minus 5, respectively, at 30 and 120 min. In contrast, the control group infused with glucose showed no change in bradykinin, A II, or PRA. Another four subjects were given a constant 200 meq sodium/100 meq potassium isocaloric diet. After metabolic balance was achieved, they were kept supine and fasting overnight. At 9 a.m. they assumed an upright position and began walking a fixed distance (200 ft) at a normal rate (3-4 ft/s). Plasma prekallikrein and kallikrein inhibitor did not change during the posture study. The plasma bradykinin rose from a base line of 0.54 plus or minus 0.01 (SEM) ng/ml to 0.96 plus or minus 0.13 at 20 min. 0.77 plus or minus 0.18 at 60 min, and 0.96 plus or minus 0.07 at 120 min. These changes parallel the increase in PRA over the same period (1.65 plus or minus 3.3 ng/ml/h to 3.6 plus or minus 0.85 at 20 min, 5.3 plus or minus 0.9 at 60 min, and 5.35 plus or minus 0.55 at 120 min). Likewise, the A II rose from 32.5 plus or minus 1.82 pg/ml to 50.8 plus or minus 3.6 at 20 min, 54.3 plus or minus 3.2 at 60 min, and 61.3 plus or minus 5.9 at 120 min. Thus, in sodium-depleted individuals, saline infusion produces a rapid fall of plasma bradykinin at a rate similar to that observed for a II and PRA. Conversely, in sodium-loaded individuals, assumption of upright posture leads to a parallel rise in A II, TPRA, and bradykinin. These studies indicate that there is a close correlation of bradykinin levels with renin activity and angiotensin II, in both acute sodium loading and assumption of upright posture, suggesting that these two systems may be physiologically interrelated.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 235559      PMCID: PMC301804          DOI: 10.1172/JCI107978

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  EFFECT OF DRUG INFUSION ON THE SYSTEMIC AND SPLANCHNIC CIRCULATION. I. BRADYKININ INFUSION IN NORMAL SUBJECTS.

Authors:  F S FERUGLIO; F GRECO; L CESANO; D INDOVINA; G SARDI; L CHIANDUSSI
Journal:  Clin Sci       Date:  1964-06       Impact factor: 6.124

2.  GENERAL CIRCULATORY ALTERATIONS INDUCED BY INTRAVENOUS INFUSIONS OF SYNTHETIC BRADYKININ IN MAN.

Authors:  F M DE FREITAS; E Z FARACO; D F DE AZEVEDO
Journal:  Circulation       Date:  1964-01       Impact factor: 29.690

3.  VARIATIONS IN PLASMA RENIN CONCENTRATION IN SEVERAL PHYSIOLOGICAL AND PATHOLOGICAL STATES.

Authors:  J J BROWN; D L DAVIES; A F LEVER; J I ROBERTSON
Journal:  Can Med Assoc J       Date:  1964-01-25       Impact factor: 8.262

Review 4.  The human plasma kallikrein-kinin system.

Authors:  R W Colman; G J Girey; R Zacest; R C Talamo
Journal:  Prog Hematol       Date:  1971

5.  Some properties of angiotensin converting enzyme in the lung in vivo.

Authors:  K K Ng; J R Vane
Journal:  Nature       Date:  1970-03-21       Impact factor: 49.962

6.  Urinary kallikrein excretion in normal man. Relationships to sodium intake and sodium-retaining steroids.

Authors:  H S Margolius; D Horwitz; R G Geller; R W Alexander; J R Gill; J J Pisano; H R Keiser
Journal:  Circ Res       Date:  1974-12       Impact factor: 17.367

7.  Hyperbradykininism: a new orthostatic syndrome.

Authors:  D H Streeten; C B Kerr; L P Kerr; J C Prior; T G Dalakos
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

8.  Relation between urinary kallikrein and renal function, hypertension, and excretion of sodium and water in man.

Authors:  A Adetuyibi; I H Mills
Journal:  Lancet       Date:  1972-07-29       Impact factor: 79.321

9.  Altered urinary kallikrein excretion in human hypertension.

Authors:  H S Margolis; R Geller; J J Pisano; A Sjoerdsma
Journal:  Lancet       Date:  1971-11-13       Impact factor: 79.321

10.  The kallikreinogen-kallikrein enzyme system of human plasma. Assay of components and observations in disease states.

Authors:  R W Colman; J W Mason; S Sherry
Journal:  Ann Intern Med       Date:  1969-10       Impact factor: 25.391

View more
  11 in total

1.  Urinary kallikrein and plasma renin activity as determinants of renal blood flow. The influence of race and dietary sodium intake.

Authors:  S B Levy; J J Lilley; R P Frigon; R A Stone
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

2.  Release of renal kallikrein to the perfusate by isolated rat kidney.

Authors:  J S Roblero; H R Croxatto; R B Albertini
Journal:  Experientia       Date:  1976-11-15

3.  Components of the renin-angiotensin system in the plasma of Bothrops jararaca.

Authors:  A C Lavras; M Fichman; E Hiraichi; M A Boucault; T Tobo
Journal:  Agents Actions       Date:  1978-01

4.  The role of chloride transport in the thick ascending limb in the pathogenesis of Bartter's syndrome.

Authors:  J R Gill
Journal:  Klin Wochenschr       Date:  1982-10-01

5.  Indomethacin and the hypotensive action of captopril in DOCA salt hypertensive rats [proceedings].

Authors:  C T Dollery; I Miyamori
Journal:  Br J Pharmacol       Date:  1980-01       Impact factor: 8.739

6.  Decreased urinary kallikrein activity and elevated blood pressure normalized by orally applied kallikrein in essential hypertension.

Authors:  A Overlack; K O Stumpe; C Ressel; R Kolloch; W Zywzok; F Krück
Journal:  Klin Wochenschr       Date:  1980-01-02

7.  Humoral and haemodynamic effects of idrapril calcium, the prototype of a new class of ACE-inhibitors, in essential hypertensive patients.

Authors:  S Taddei; L Ghiadoni; P Mattei; I Sudano; P Duranti; S Favilla; A Virdis; A Romagnoli; M Criscuoli; A Coppini
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

8.  The effect of angiotensin I converting enzyme inhibitor (SQ 20881) on the release of prostaglandins by rabbit kidney, in vivo.

Authors:  E J Johns; R Murdock; B Singer
Journal:  Br J Pharmacol       Date:  1977-08       Impact factor: 8.739

Review 9.  The renal kallikrein-kinin system in human and in experimental hypertension.

Authors:  O A Carretero; A G Scicli
Journal:  Klin Wochenschr       Date:  1978

Review 10.  Genetics of Human Primary Hypertension: Focus on Hormonal Mechanisms.

Authors:  Worapaka Manosroi; Gordon H Williams
Journal:  Endocr Rev       Date:  2019-06-01       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.